



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/992,433	11/16/2001	Sikander Randhava	13909-00002	6093

7590                    09/17/2002

KATTEN MUCHIN ZAVIS  
Attention : Patent Administrator  
Suite 1600  
525 West Monroe Street  
Chicago, IL 60661-3693

[REDACTED] EXAMINER

TATE, CHRISTOPHER ROBIN

[REDACTED] ART UNIT      [REDACTED] PAPER NUMBER

1651

DATE MAILED: 09/17/2002

U

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	Application No. <b>09/992,433</b>	Applicant(s) <b>Randhava et al.</b>						
	Examiner <b>Christopher Tate</b>	Art Unit <b>1651</b>						
								
<i>-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --</i>								
<b>Period for Reply</b> A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE <u>1</u> MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. <ul style="list-style-type: none"> <li>- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.</li> <li>- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.</li> <li>- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.</li> <li>- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).</li> <li>- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).</li> </ul>								
<b>Status</b> <p>1) <input checked="" type="checkbox"/> Responsive to communication(s) filed on <u>Jan 27, 2002</u></p> <p>2a) <input type="checkbox"/> This action is <b>FINAL</b>.      2b) <input checked="" type="checkbox"/> This action is non-final.</p> <p>3) <input type="checkbox"/> Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i>, 1935 C.D. 11; 453 O.G. 213.</p>								
<b>Disposition of Claims</b> <p>4) <input checked="" type="checkbox"/> Claim(s) <u>1-27</u> is/are pending in the application.</p> <p>4a) Of the above, claim(s) _____ is/are withdrawn from consideration.</p> <p>5) <input type="checkbox"/> Claim(s) _____ is/are allowed.</p> <p>6) <input type="checkbox"/> Claim(s) _____ is/are rejected.</p> <p>7) <input type="checkbox"/> Claim(s) _____ is/are objected to.</p> <p>8) <input checked="" type="checkbox"/> Claims <u>1-27</u> are subject to restriction and/or election requirement.</p>								
<b>Application Papers</b> <p>9) <input type="checkbox"/> The specification is objected to by the Examiner.</p> <p>10) <input type="checkbox"/> The drawing(s) filed on _____ is/are a) <input type="checkbox"/> accepted or b) <input type="checkbox"/> objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).</p> <p>11) <input type="checkbox"/> The proposed drawing correction filed on _____ is: a) <input type="checkbox"/> approved b) <input type="checkbox"/> disapproved by the Examiner. If approved, corrected drawings are required in reply to this Office action.</p> <p>12) <input type="checkbox"/> The oath or declaration is objected to by the Examiner.</p>								
<b>Priority under 35 U.S.C. §§ 119 and 120</b> <p>13) <input type="checkbox"/> Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</p> <p>a) <input type="checkbox"/> All b) <input type="checkbox"/> Some* c) <input type="checkbox"/> None of:</p> <ol style="list-style-type: none"> <li>1. <input type="checkbox"/> Certified copies of the priority documents have been received.</li> <li>2. <input type="checkbox"/> Certified copies of the priority documents have been received in Application No. _____.</li> <li>3. <input type="checkbox"/> Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> </ol> <p>*See the attached detailed Office action for a list of the certified copies not received.</p> <p>14) <input type="checkbox"/> Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e). a) <input type="checkbox"/> The translation of the foreign language provisional application has been received.</p> <p>15) <input type="checkbox"/> Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.</p>								
<b>Attachment(s)</b> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 33%;"><p>1) <input type="checkbox"/> Notice of References Cited (PTO-892)</p></td> <td style="width: 33%;"><p>4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____</p></td> </tr> <tr> <td>2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)</td> <td><p>5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)</p></td> </tr> <tr> <td>3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____</td> <td><p>6) <input type="checkbox"/> Other: _____</p></td> </tr> </table>			<p>1) <input type="checkbox"/> Notice of References Cited (PTO-892)</p>	<p>4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____</p>	2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	<p>5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)</p>	3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____	<p>6) <input type="checkbox"/> Other: _____</p>
<p>1) <input type="checkbox"/> Notice of References Cited (PTO-892)</p>	<p>4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____</p>							
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	<p>5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)</p>							
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____	<p>6) <input type="checkbox"/> Other: _____</p>							

Art Unit: 1651

## DETAILED ACTION

### *Election/Restriction*

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-23, drawn to an oral composition for treating BPH comprising a saw palmetto extract and a controlled release system whereby the system comprises a soluble coating formed of a material impervious to gastric acid, classified in class 424, subclass 727 and 457, for example.
- III. Claims 24-27, drawn to a composition comprising a saw palmetto extract and one or more antispasmodic compounds such as peppermint, classified in class 424, subclass 747, for example.

The inventions are distinct, each from the other because of the following reasons:

The products of Groups I and II are distinct, each from the other, because the product of Group I requires a saw palmetto extract and a controlled release system, whereas the product of Group II does not necessarily require a controlled release system. Further, the product of Group II requires an antispasmodic from among those recited in claim 24, whereas the product of Group I does not necessarily require an antispasmodic, nor an antispasmodic from among those recited in claim 24.

Art Unit: 1651

The inventions above are independent and distinct, each from the other. The search for each of the above inventions is not co-extensive particularly with regard to the literature search. Further, a reference which would anticipate the invention of one group would not necessarily anticipate or even make obvious another group. Finally, the consideration for patentability is different in each case. Thus, it would be an undue burden to examine all of the above inventions in one application.

Because these inventions are distinct for the reasons given above and the search required for Group I is not necessarily required for Group II, restriction for examination purposes as indicated is proper.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(l).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christopher R. Tate whose telephone number is (703) 305-7114. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Wityshyn, can be reached at (703) 308-4743. The Group receptionist may be reached at (703) 308-0196. The fax number for art unit 1651 is (703) 308-4242.

  
Christopher R. Tate  
Primary Examiner, Group 1651